We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » LEO Pharma Gets FDA Complete Response Letter for Eczema Drug
LEO Pharma Gets FDA Complete Response Letter for Eczema Drug
The FDA has issued a complete response letter (CRL) to LEO Pharma, requesting additional information regarding a device component for the Danish drugmaker’s moderate-to-severe atopic dermatitis candidate tralokinumab.